Patient info Open main menu

Pramipexole Teva 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
2.62 mg
Contains active substance:

Patient leaflet - Pramipexole Teva 2.62 mg prolonged-release tablets

What Pramipexole Teva is and what it is used for

Pramipexole Teva contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

Pramipexole Teva is used to treat the symptoms of primary Parkinson’s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease).

What you need to know before you take Pramipexole Teva

Do not take Pramipexole Teva

  • if you are allergic to pramipexole or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking Pramipexole Teva. Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:

  • Kidney disease.
  • Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.
  • Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced Parkinson’s disease and are also taking levodopa, you might develop dyskinesia during the up-titration of Pramipexole Teva.
  • Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). In particular, you may experience forward flexion of the head and neck (also called antecollis), forward bending of the lower back (also called camptocormia) or sidewards bending of the back (also called pleurothotonus or Pisa Syndrome). If this happens, your doctor may want to change your medication.
  • Sleepiness and episodes of suddenly falling asleep.
  • Psychosis (e.g. comparable with symptoms of schizophrenia).
  • Vision impairment. You should have regular eye examinations during treatment with Pramipexole Teva.
  • Severe heart or blood vessels disease. You will need to have your blood pressure checked regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).

Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.

Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion, loss of reality). Your doctor may need to adjust or stop your dose.

Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your Pramipexole Teva treatment. If the problems persist more than a few weeks, your doctor may need to adjust your treatment.

Tell your doctor if you are developing an inability of keeping your body and neck straight and upright (axial dystonia). If this happens, your doctor may want to adjust or change your medication.

Pramipexole Teva is a specially designed tablet from which the active ingredient is gradually released, once the tablet has been ingested. Parts of tablets may occasionally be passed and seen in the stool (faeces) and may look like whole tablets. Inform your doctor if you find tablet pieces in your faeces.

Children and adolescents

Pramipexole Teva is not recommended for use in children or adolescents under 18 years.

Other medicines and Pramipexole Teva

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

You should avoid taking Pramipexole Teva together with antipsychotic medicines.

Take care if you are taking the following medicines:

  • cimetidine (to treat excess stomach acid and stomach ulcers);
  • amantadine (which can be used to treat Parkinson’s disease);
  • mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia);
  • zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system);
  • cisplatin (to treat various types of cancers);
  • quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria));
  • procainamide (to treat irregular heart beat).

If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with Pramipexole Teva.

Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases Pramipexole Teva may affect your ability to drive and operate machinery.

Pramipexole Teva with food, drink and alcohol

You should be cautious while drinking alcohol during treatment with Pramipexole Teva.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will then discuss with you if you should continue to take Pramipexole Teva.

The effect of Pramipexole Teva on the unborn child is not known. Therefore, do not take Pramipexole Teva if you are pregnant unless your doctor tells you to do so.

Pramipexole Teva should not be used during breast-feeding. Pramipexole Teva can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of Pramipexole Teva is unavoidable, breast-feeding should be stopped.

Driving and using machines

Pramipexole Teva can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.

Pramipexole Teva has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s disease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.

How to take Pramipexole Teva

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The doctor will advise you on the right dosing.

Take Pramipexole Teva Prolonged-release Tablets only once a day and each day at about the same time.

You can take Pramipexole Teva with or without food. Swallow the tablets whole with water.

Do not chew, divide or crush

the prolonged-release tablets.

If you do, there is a danger you

could overdose, because the

medicine may be released into

your body too quickly.

During the first week, the

recommended daily dose is

0.26 mg pramipexole. The dose

will be increased every 5-7 days

as directed by your doctor until your symptoms are controlled (maintenance dose).

Ascending dose schedule of Pramipexole Teva Prolonged-release Tablets
WeekDaily dose (mg)Number of tablets
10.26One Pramipexole Teva 0.26 mg Prolonged-release Tablet.
20.52

One Pramipexole Teva 0.52 mg Prolonged-release Tablet,

OR

two Pramipexole Teva 0.26 mg Prolonged-release Tablets.

31.05

One Pramipexole Teva 1.05 mg Prolonged-release Tablet,

OR

two Pramipexole Teva 0.52 mg Prolonged-release Tablets,

OR

four Pramipexole Teva 0.26 mg Prolonged-release Tablets.

The recommended maintenance dose is 1.05 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your dose up to a maximum of 3.15 mg of pramipexole a day. A lower maintenance dose of one Pramipexole Teva 0.26 mg Prolonged-release Tablet a day is also possible.

Patients with kidney disease

If you have kidney disease, your doctor may advise you to take the usual starting dose of 0.26 mg prolonged-release tablets only every other day for the first week. After that, your doctor may increase the dosing frequency to one 0.26 mg prolonged-release tablet every day. If a further dose increase is necessary, your doctor may adjust it in steps of 0.26 mg pramipexole.

3

Package leaflet: Information for the patient

What is in this leaflet

Fold Fold

If you have serious kidney problems, your doctor may need to switch you to a different pramipexole medicine. If during treatment your kidney problems get worse, you should contact your doctor as soon as possible.

If you are switching from pramipexole (immediate release) tablets

Your doctor will base your dose of pramipexole prolonged-release tablets on the dose of pramipexole (immediate release) tablets you were taking.

Take your pramipexole (immediate release) tablets as normal the day before you switch. Then take your pramipexole prolonged-release tablets next morning and do not take any more pramipexole (immediate release) tablets.

If you take more Pramipexole Teva than you should

If you accidentally take too many tablets,

  • Contact your doctor or nearest hospital casualty department immediately for advice.
  • You may experience vomiting, restlessness, or any of the side effects as described in section 4.

If you forget to take Pramipexole Teva

If you forget to take a dose of Pramipexole Teva, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.

If you forget for more than 12 hours, simply take the next single dose at the usual time. Do not take a double dose to make up for a forgotten tablet dose.

If you stop taking Pramipexole Teva

Do not stop taking Pramipexole Teva without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.

If you suffer from Parkinson’s disease you should not stop treatment with Pramipexole Teva abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:

  • akinesia (loss of muscle movement),
  • rigid muscles,
  • fever,
  • unstable blood pressure,
  • tachycardia (increased heart rate),
  • confusion,
  • depressed level of consciousness (e.g. coma).

If you stop or reduce Pramipexole Teva you may also develop a medical condition called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or pain. If you experience these symptoms you should contact your physician.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You may experience the following side effects:

Very common: may affect more than 1 in 10 people

  • dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
  • sleepiness
  • dizziness
  • nausea (sickness).

Common: may affect up to 1 in 10 people

  • urge to behave in an unusual way
  • hallucinations (seeing, hearing or feeling things that are not there)
  • confusion
  • tiredness (fatigue)
  • sleeplessness (insomnia)
  • excess of fluid, usually in the legs (peripheral oedema)
  • headache
  • hypotension (low blood pressure)
  • abnormal dreams
  • constipation
  • visual impairment
  • vomiting (being sick)
  • weight loss including decreased appetite.

Uncommon: may affect up to 1 in 100 people

  • paranoia (e.g. excessive fear for one’s own well-being)
  • delusion
  • excessive daytime sleepiness and suddenly falling asleep
  • amnesia (memory disturbance)
  • hyperkinesia (increased movements and inability to keep still)
  • weight increase
  • allergic reactions (e.g. rash, itching,

    hypersensitivity)

  • fainting
  • cardiac failure (heart problems which can cause shortness of breath or ankle swelling)*
  • inappropriate antidiuretic hormone secretion*
  • restlessness
  • dyspnoea (difficulties to breathe)
  • hiccups
  • pneumonia (infection of the lungs)
  • inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:

    • strong impulse to gamble excessively despite serious personal or family consequences
    • altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive
    • uncontrollable excessive shopping or spending
    • binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
  • delirium (decreased awareness, confusion, loss of reality).

Rare: may affect up to 1 in 1,000 people

  • mania (agitation, feeling elated or over-excited).

    Not known: frequency cannot be estimated from the available data

    • After stopping or reducing your Pramipexole Teva treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviors; he will discuss ways of managing or reducing the symptoms.

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store Pramipexole Teva

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Pramipexole Teva Prolonged-release Tablets contains

The active substance is pramipexole.

Each tablet contains 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg or 3.15 mg pramipexole as 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, or 4.5 mg pramipexole dihydrochloride monohydrate, respectively.

The other excipients are hypromellose, calcium hydrogen phosphate, magnesium stearate and colloidal anhydrous silica.

What Pramipexole Teva Prolonged-release Tablets looks like and contents of the pack

Pramipexole Teva 0.26 mg Prolonged-release Tablets: The round tablets of 9 mm diameter are white or nearly white, have a flat surface with bevelled edges and are marked with 026 on one side.

Pramipexole Teva 0.52 mg Prolonged-release Tablets: The round tablets of 10 mm diameter are white or nearly white, biconvex and are marked with 052 on one side.

Pramipexole Teva 1.05 mg Prolonged-release Tablets: The round tablets of 10 mm diameter are white or nearly white, biconvex and are marked with 105 on one side.

Pramipexole Teva 1.57 mg Prolonged-release Tablets: The round tablets of 10 mm diameter are white or nearly white, biconvex and are marked with 157 on one side.

Pramipexole Teva 2.1 mg Prolonged-release Tablets: The round tablets of 10 mm diameter are white or nearly white, biconvex and are marked with 210 on one side.

Pramipexole Teva 2.62 mg Prolonged-release Tablets: The round tablets of 10 mm diameter are white or nearly white, biconvex and are marked with 262 on one side.

Pramipexole Teva 3.15 mg Prolonged-release Tablets: The round tablets of 11 mm diameter are white or nearly white, have a flat surface with bevelled edges and are marked with 315 on one side.

Pramipexole Teva is available in packs containing 10, 30 and 100 prolonged-release tablets in aluminium blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

TEVA UK Limited, Ridings Point, Whistler Drive, Castleford, WF10 5HX, United Kingdom

Manufacturer

Laboratorios Normon, S.A.

Ronda de Valdecarrizo, 6, Tres Cantos, Madrid, 28760, Spain

This leaflet was last revised in08/2024.

PL 00289/1873

PL 00289/1874

PL 00289/1875

PL 00289/1876

PL 00289/1877

PL 00289/1878

PL 00289/1879

4

5

6

193288_s1

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00289/1878

Last revision stated in the text: August 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Pramipexole Teva 2.62 mg prolonged-release tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Pramipexole
Strength 2.62 mg
Pharmaceutical form Modified-release tablet
The round tablets of 9 mm diameter are white or nearly white, have a flat surface with beveled edges and are marked with 026 on one side
How is it taken Oral
Excipients Hypromellose, Calcium hydrogen phosphate, Magnesium stearate, Silica, colloidal anhydrous
Pack sizes 30 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Anti-Parkinson drugs, dopamine agonists
  1. N Nervous system drugs
    1. N04 Anti-parkinson drugs
      1. N04B Dopaminergic agents
        1. N04BC Dopamine agonists
          1. N04BC05 pramipexole
Marketing authorisation PL 00289/1878 (first authorised 22 December 2014)
Marketing authorisation holder Teva UK Limited
Codes GTIN 5017007065821 · BNF 04090100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.